 |
|
Curriculum Vitae For:
Theodore Thomas Wagner, III, M.D.
Northeast Indiana Research, LLC
2512 East Dupont Road, Suite # 100
Fort Wayne, Indiana 46825
Education:
| 1990-194 |
The Ohio State University, Columbus, OH, Doctor of Medicine |
| 1986-1990 |
1986-1990 Miami University, Oxford, OH, Bachelor of Arts, Microbiology- Cum Laude
|
Work Experience:
| 1999-Present |
Northeast Indiana Urology, PC, Fort Wayne, Indiana |
| 1999-Present |
Northeast Indiana Research, Fort Wayne, Indiana |
| 1996-1999 |
Urology Resident, Ohio State University, Columbus, OH |
| 1994-1996 |
Surgical Resident, Ohio State University, Columbus, OH |
Credentials:
| Medical License: |
Indiana #01050471A |
| Board Certification: |
March 2001 |
Hospital Affiliations:
| 1999-Present |
Urologist, Lutheran Hospital of Indiana, Fort Wayne, Indiana |
| 1999-Present |
Urologist, Parkview Memorial Hospital, Fort Wayne, Indiana |
| 1999-Present |
Urologist, Parkview Whitley County Memorial Hospital, Columbia City, Indiana
|
| 1999-Present |
Urologist, Kosciosko Community Hospital, Warsaw, Indiana |
| 1999-Present |
Urologist, Huntington Memorial Hospital, Huntington, Indiana |
| 1999-Present |
Urologist, Wells Community Hospital, Bluffton, Indiana |
| 2000-Present |
Urologist, Dupont Surgery Center, Fort Wayne, Indiana |
| 2001-Present |
Urologist, Dupont Hospital, Fort Wayne, Indiana |
Professional Affiliations:
| 1998--Resident representative of the Executive Committee
For the Ohio Urological Society |
| The Ohio Urological Association |
| American Urological Association |
| The American Medical Association |
Presentations and Honors:
| T.T. Wagner, R.R. Bahnson: Charge and length of stay analysis
For radical retropubic prostatectomy and brachytherapy. Poster
Session presented at the AUA Annual Meeting, San Diego, CA,
June, 1998
|
| T.T. Wagner, R.R. Bahnson: The early morbidity associated with
Prostate brachytherapy. Podium session, The Ohio Urologic Society, Columbus, OH, March 1998
|
| First Place, Ohio Urological Society Resident Research Contest, 1998 |
| T.T. Wagner, R.R. Bahnson: Charge and length of stay analysis for radical retropubic prostatectomy and brachytherapy. Podium session, North Central Section of the AUA, Monterey, CA, September 1997 |
| Recipient of Pfizer Scholars in Urology Award, 1997 |
| First Place, Ohio Urological Society Resident Research Contest, 1997 |
| Second Place, Pittsburgh Urological Society Research Contest, 1997 |
| Fifth Place, Columbus Children’s Hospital Research Contest, 1997 |
Publications:
- T.T. Wagner, R.R. Bahnson: Carcinoma of the Prostate. Update
For Psychiatrists, 1997
- S.A. Koff, T.T. Wagner, V.K. Jayanthi: Relationship amoung
Dysfunctional elimination syndromes, primary vesicoureteral reflux, and urinary tract infections in children.
J. of Urol. 160(3, part 2/2), 1998
Research Activities:
- Safety and Tolerability of Long-term Administration of XXXX.
- A Repeated-Dose Evaluation of Analgesic Use and Safety of XXXXX in Patients
with Chronic Non-Malignant Pain.
- A Repeated-Dose Evaluation of Analgesic Use and Safety of XXXXX In Patients
with Chronic Cancer Pain
- The Safety and Activity of Three Doses of XXXXX Compared to XXXXX in the
treatment of Herpes Zoster in Immunocompetent Adults.
- A Randomized, Multicenter, Open-Label, Dose-Ranging Study Comparing the
Safety and Efficacy of XXXX to XXXX in Women with Endometriosis-Associated
Pain.
- A Phase III, Efficacy and Safety Study Comparing Escalating doses of XXXX
to 5mg, 6mg, Doses of XXXX or Placebo in the Treatment of Male Erectile Dysfunction.
- A Phase III, Efficacy and Safety Study of Four Fixed Doses of XXXX SL Tablet
versus Placebo in the Treatment of Male Erectile Dysfunction
- A Phase III, Long-Term, Open-Label, Flexible Dose, Efficacy and Safety Study
of XXXX Tablets in the Treatment of Male Erectile Dysfunction
- A Phase II, Safety Study of 5 mg XXXXX versus Placebo in the Treatment of
Patients diagnosed with Male Erectile Dysfunction Following a Bilateral Nerve-Sparing
Radical Retropubic Prostatectomy.
- A Randomized, Multicenter, Double-Blind, Double-Dummy Comparative Trial
of XXXX and XXXX for the Treatment of Bacterial Prostatitis.
- A Phase II, Open-Label Trial of XXXX in Complicated Urinary Tract Infections.
- A Randomized, Double-Blind, Multicenter, Phase II/III Comparison of XXXX
to XXXX in the Treatment of Complicated Urinary Tract Infection and Pyelonephritis.
- Phase II, Multicenter, Open-label Study of XXXX, Administered as a Subcutaneous,
Continuous Infusion for 57 to 85 days (8 to 12 weeks) in Patients Undergoing
Radiation Therapy Interstitial Seed Implantation or Other Radiation Therapy.
- Clinical Trail to Assess the Efficacy and Safety of XXXX in Hormone Refractory
Stage D2 Prostate Cancer
- A Multicenter, Randomized, Open-Label Trial to Compare Bone Mineral Density
and Fat Free Mass in Men Given Either XXXX 10.8mg Depot or XXXX 150mg for
Treatment of Prostate Cancer
- A Randomized, Double-Blind comparative trial of XXXX versus Placebo in Patient
with Early Prostate Cancer
- A Phase III, Multicenter, Open-Label, Randomized Study of XXXX vs. XXXX
plus daily XXXX in Patients with Prostate Cancer who are Candidates for Initial
Hormonal Therapy
- A Randomized, Double-Blind, Placebo Controlled, Two-Year, parallel Group
Study of the Efficacy and Safety of XXXX 0.5mg in the Treatment and Prevention
of Progression of Benign Prostatic Hyperplasia.
- A Phase II/III, Double-Blind, Placebo Controlled, Dose-Finding Study of
the Safety and Efficacy of XXXX in Patients with Symptomatic Benign Prostatic
Hyperplasia (BPH)
- An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo
Lead-In Study of XXXX Capsules, 0.4mg Daily versus XXXX Capsules, 5mg (with
XXXX) daily in Patients with the Signs and Symptoms of Benign Prostatic Hyperplasia.
- Clinical Efficacy and Safety of XXXX as Compared to XXXX and Placebo. A
Phase III, Randomized, Double-Blind, Multinational Study in Patients with
Detrusor Overactivity and symptoms of Frequency, Urge Incontinence and Urgency.
- Clinical Efficacy and Tolerability/Safety of XXXX Prolonged Release Capsules
and XXXX Immediate Release Tablets vs. Placebo. A Randomzied, Double-Blind,
Placebo controlled, Multinational Study in Patients with Symptoms of Overactive
Bladder
- Clinical Trial to Investigate XXXX Insert as an Intraurethral Device Intended
to be used for the Management of Stress Urinary Incontinence in Adult Females
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study to Assess Efficacy and Safety of Daily Oral Administration of XXXX versus Placebo in Male and Female Subjects with Overactive Bladder.
- An Evaluation on Effect of 20mg XXXX on Sperm Concentration in Normal Healthy
Subjects or Subject with Mild Erectile Dysfunction.
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of XXXX
for the Treatment of Male Erectile Dysfunction in an At-Home Setting.
- An Open-Label, Continuation Trial of XXXX in Male Erectile Dysfunction Patients
Who Previously Participated in a Parent Study.
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess Duration
of Responsiveness to XXXX in Patients with Erectile Dysfunction.
- A Randomized, Double-Blind, Crossover Study of XXXX Compared with XXXX for
the Treatment of Patients with Erectile Dysfunction.
- Long-Term Efficacy and Safety of XXXX 10mg OD on the Risk of Acute Urinary
Retention and the Need for Surgery in Patients with BPH. A Two-Year, Randomized,
Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.
- An Open-Label Comparison of Neoadjuvant Hormonal Therapy (NHT) with XXXX
100mg IM or XXXX 7.5mg IM in Patients with Prostate Cancer Planned to Undergo
Brachytherapy or External-beam Radiation Therapy.
- Evaluation of the Use of a Unique Testosterone XXXX Formulation in Males
With a Testosterone Level < 300 ng/dL.
- Efficacy and Safety of XXXX Compared With Placebo in Subjects with Stress
Urinary Incontinence.
- Long Term Monitoring of Safety in Subjects Treated with XXXX for Stress
Urinary Incontinence.
- A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Study of
the Efficacy and Safety of XXXX Cream in Premenopausal Patients With Female
Sexual Arousal Disorder.
- A Multi-Center, Double-Blind, Double-Dummy, Randomized, Placebo and Tamsulosin
Controlled Parallel Group Study to Assess the Efficacy and Safety of XXXX
in Subjects with Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction.
- A Two Phase, Double-Blinded, Randomized, Multicenter, Parallel-Design Study
of XXXX Capsules, 0.4 mg Daily versus Placebo, in Male Patients with Acute
Urinary Retention Related to Benign Prostatic Hyperplasia.
- A Placebo-Controlled, Double-Blind, Randomized, Crossover Study of the Efficacy
and Safety of XXXX in the Treatment of Rapid Ejaculation.
- A Multi-Center, Randomized, Double-Blind, Placebo Controlled Crossover Trial
to Assess the Effect of XXXX 160mg on Penile Rigidity and XXXX in Patients
with Mild to Moderate Erectile Dysfunction.
- A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of
XXXX to That of XXXX in the Treatment of Chronic Prostatitis.
- A Randomized Double Blind Placebo Controlled Study of XXXX Provided to Patients
with Erectile Dysfunction.
- A Randomized Placebo Controlled Double Blind Parallel Design Phase III Trial
of the Efficacy and Safety of XXXX in Patients with Erectile Dysfunction.
- A Four-Week "Proof of Concept" Study to Determine the Safety Tolerability
and Efficacy of Oral XXXX in Patients with Symptoms of Urinary Urgency and
Frequency with or without Incontinence.
- Multi Center Double Blind Study of the Safety and Efficacy of XXXX vs. Placebo
for Treatment of Hypogondal Men Who are Non-Responders to XXXX.
- Prospective Randomized, Double-Blind Multi-Center Comparative Trial To Evaluate
the Efficacy and Safety of XXXX Once-Daily (QD) Modified Release (XXXX MR)
Tablets 1000mg Conventional XXXX 500mg Tablets in the 7-14 Day Treatment of
Patients With Complicated Urinary Tract Infections (cUTI) or Acute Uncomplicated
Pyelonephritis.
- Phase I/II Dose Escalation and Efficacy Trial of XXXX in Patients With Metastatic
Hormone-Refractory Prostate Cancer.
- Randomized, Double-Blind, Placebo-Controlled, 2-Way Crossover Study To Investigate
The Time-to-Onset (time to reach > 55% of penile rigidity, as measured
by the RigiScan device), of a Single Oral Dose of XXXX Compared To Placebo
In Male Patients With Erectile Dysfunction.
- A Randomized, Double Blind, Multi Center, Fixed Dose, Cross Over Study To
Investigate The Efficacy and Safety of 20mg of XXXX Given on Demand in Comparison
To 100mg of XXXX Given on Demand In Males With Erectile Dysfunction And a
Diagnosis of Diabetes Mellitus and/or Hypertension and/or Hyperlipidemia.
- An Open-Label Study To Evaluate The Feasibility of Switching To Treatment
With An LHRH Agonist Following 4 Weeks of Treatment With XXXX In Patients
With Prostate Cancer.
- A Randomized, Placebo-Controlled, Double-Blind, Crossover Design Phase 2
Study of the Efficacy and Safety of XXXX In Patients With Erectile Dysfunction
Using Rigidity and Tumescence Monitoring.
- A Multicenter, Fixed Dose Study With a Double-Blind, Randomized, Placebo-Controlled,
Parallel Group Phase, And An Open Label Phase To Investigate The Time To Onset
of Activity of XXXX.
- A Double-Blind, Randomized, Crossover Evaluation of Safety And Efficacy
of XXXX With Visual Sexual Stimulation In Patients With Erectile Dysfunction.
- Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
to Assess the Safety and Efficacy of XXXX in Delaying the Systemic Progression
of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence
With Rising PSA Levels After Prostatectomy and Radiotherapy or Radiotherapy
Alone for Localized Disease.
- XXXX to the Submucosa of the Bladder Outlet and Proximal Urethra for the Treatment of Stress Urinary Incontinence.
- A Phase 3B Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel
Group Study of XXXX in Subjects with Overactive Bladder.
- An Open-Label Study to Evaluate the Feasibility of Switching to Treatment
with an LHRH Agonist Following 12 Weeks of Treatment with XXXX in Patients
with Prostate Cancer.
- A Multicenter, Open-Label, Flexible Dose Escalation Study to Evaluate the
Correlation Between Event Log Parameters, Self Esteem/Overall Relationships,
and Efficacy of XXXX in Men with Erectile Dysfunction.
- A Phase III, Multinational, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled
24-week Study to Evaluate the Efficacy and Safety of XXXX in Naturally Menopausal
Women with Hypoactive Sexual Desire Disorder on Concurrent Oral Hormone Replacement
Therapy.
- A Phase III, Multinational, Randomized, Double-Blind, Parallel Group, Placebo-Controlled
24-week Study to Evaluate the Efficacy and Safety of XXXX in Women with Hypoactive
Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy Who Have
Undergone Hysterectomy and Bilateral Oophorectomy.
- A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose, Multi-Center
Study to Evaluate the Efficacy, Safety and Toleration of Oral XXXX Administered
for 12 Weeks to Post-Menopausal Women Who Have Been Diagnosed With Female
Sexual Arousal Disorder.
- A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Fixed Dose,
Multi-Center Study to Evaluate the Efficacy, Safety and Toleration of Oral
XXXX Administered for 12 Weeks to Pre-Menopausal Women Who Have Been Diagnosed
With Female Sexual Arousal Disorder.
- A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Efficacy
and Safety of XXXX in the Treatment of Rapid Ejaculation.
- A Randomized, Double-Blind, Parallel Placebo-Controlled Study in Men with
Erectile Dysfunction to Evaluate the Efficacy and Safety of XXXX when Sexual
Attempts Occur at Specific Time Points after Dosing.
- Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety
of a Partial XXXX, in Women with Stress Urinary Incontinence or Mixed Urinary
Incontinence.
- A Multi-Center, Multi-Nation Observational, Study to Document Treatment
and Standard of Care for Subjects with Metastatic Hormone Refractory Prostate
Cancer.
- An Open-Label, Multi-Center Extension Study to Evaluate the Safety, Toleration
and Sustained Efficacy of Oral XXXX Administered to Women Who Have Been Diagnosed
with Female Sexual Arousal Disorder.
- A Double-Blind, Placebo-Controlled, Randomized US Study to Evaluate the
Effect of XXXX Prolonged Release on Nocturia in Patients with Symptoms of
Overactive Bladder (OAB).
- Collection of Sexual Information in a Four-Week Outpatient Study in Normal
Women.
- A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study of the
Efficacy and Safety of XXXX 0.5mg Administered Once Daily for Four Years to
Reduce the Risk of Biopsy-Detectable Prostate Cancer.
- A Placebo-Controlled, Randomized, Double-Blind Parallel Group, Dose-Finding,
At-Home Study to Evaluate the Efficacy and Safety of Intranasally Administered
XXXX in Subjects with Male Erectile Dysfunction.
- A Multi-Center, Double-Blind, Placebo-Controlled, Dose-Titration Study of
XXXX Transdermal Systems in Patients with Overactive Bladder.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety
and Efficacy of XXXX Topical Solution in Patients with Interstitial Cystitis.
- Phase III, Pharmacokinetic, Safety, and Efficacy Study of a Six-Month Depot
Formulation of XXXX in Subjects with Prostatic Adenocarcinoma.
- Prospective, Randomized, Double-Blind, Placebo-Controlled Evaluation of
Topical XXXX Administered at Home for the Treatment of Premenopausal Women
with Female Sexual Arousal Disorder (FSAD).
- A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Efficacy
and Safety of XXXX in the Treatment of Rapid Ejaculation.
- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating
the Efficacy, Safety, and Reliability of 10mg XXXX Administered for 12 weeks
Compared to Placebo in Subjects with Erectile Dysfunction and a Demonstrated
Successful First Response to 10mg XXXX.
- The Effect of XXXX Compared to Placebo on Bone Mineral Density in Patients
Undergoing Androgen Deprivation Therapy.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose,
Multi-Center Study to Evaluate the Efficacy, Safety and Toleration of Oral
XXXX Administered for 12 weeks to Post-Menopausal Women Receiving Hormone
Replacement Therapy and Who Have Been Diagnosed with Female Sexual Arousal
Disorder.
- Prospective, Observational Registry Study of the Management of Men with
Symptomatic Benign Prostatic Hyperplasia (BPH): Observational Registry in
BPH Initial Treatment (Orbit) Alpha-Testing Phase.
- A Double-Blind, Randomized, Crossover Evaluation of Safety and Efficacy
of XXXX Administered at Home in Patients with Erectile Dysfunction.
- A Double-Blind, Placebo-Controlled, Multicenter Randomized, Phase-3 Study
of XXXX in the Treatment of Anemia in Cancer Subjects Not Currently Treated
with Chemotherapy or Radiotherapy.
- An Evaluation of Semen Characteristics After 40 Weeks Daily Dosing with
20mg XXXX.
- A Multicenter, Open Label, Flexible Dose Study To Investigate the Use Patterns
of XXXX and the Ability of Investigators to Further Optimize Subject Satisfaction
With XXXX Through Customized Instruction.
- The Safety of XXXX on Sperm Motility in Healthy Male Subjects.
- An Open-Label, Randomized, Multi-Center, Parallel Group Comparison of the
Efficacy and Safety of XXXX at Two Different Dosing Regimens in Patients with
Prostate Cancer Dosed for Thirteen 28-Day Cycles.
- A Double-Blind, Randomized, Placebo-Controlled Trial of XXXX for the Treatment
of Chronic Non-Bacterial Prostatitis.
- A Double-Blind, Randomized, Parallel Group Trial of XXXX Extended Release
Tablets or Placebo in Combination with XXXX for the Treatment of Lower Urinary
Tract Symptoms.
- A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo-Controlled,
Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of
XXXX Sustained Release in Subjects with Overactive Bladder Syndrome.
- A Phase 2B, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group
Dose Response Study to Assess the Efficacy and Safety of Oral XXXX In Men
With Premature Ejaculation.
- A Double-Blinded, Randomized, Evaluation of the Safety and Efficacy of XXXX
in Subjects with Erectile Dysfunction.
- A Multicenter, Randomized, Paralled Group, Double-Blind, Placebo Controlled
Flexible Dose Study with an Open-Label Extension to Assess the Efficacy and
Safety of XXXX in the Treatment of Men With Erectile Dysfunction (ED) and
Concomitant Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic
Hyperplasia (BPH) in the United States.
- An Observational Study To Evaluate Patient Reported Outcomes In Subjects
With and Without Premature Ejaculation.
- XXXX Therapy for Non-Responders to 5g of XXXX.
- A Phase 2 Randomized, Double-Blind, Dose-Ranging Efficacy and Safety Study
of XXXX (10mg, 25mg, 50mg), XXXX (50mg) Each vs. Placebo in Subjects with
Erectile Dysfunction.
- Evaluation of the Effect of Transdermal Testosterone Supplementation on
Glycemic Control, Body Composition, and Lipid Concentrations in Hypogonadal
Men With Non-Insulin-Dependent Diabetes Mellius.
- Evaluation of the Safety and Tolerability of XXXX When Co-Administered With
a PDE5 Inhibitor in Men With Erectile Dysfunction and Hypogonadism.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter,
52-week Study to Evaluate the Efficacy the Efficacy and Safety of Transdermal
Patches Delivering 150 or 300 ?/day Testosterone in Menopausal Women With
Low Libido Not Receiving Systemic Estrogen or Estrogen Progestin Therapy.
- A Double-Blind, Randomized, 6-Month Evaluation of the Safety and Efficacy
of Topical XXXX in Hysterectomized Women With Female Sexual Arousal Disorder
(FSAD).
- A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate XXXX in
the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy
for Non-Metastatic Prostate Cancer.
- A Phase II, Placebo-Controlled, Double-Blind, Dose-Ranging Randomized, Multi-Center
Study of XXXX in Older Hypogonadal Males ages 6-80: Effect on Body Composition,
Libido, and Physical and Sexual Functioning.
- A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 2
Dose Ranging Trial To Assess the Safety and Efficacy of XXXX Tablets in Male
Subjects with Erectile Dysfunction.
- A Multicenter, Parallel-Arm, Placebo-Controlled, Double-Blind Study to Evaluate
the Efficacy and Safety of XXXX Administered Once Daily to Men with Lower
Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
- Effect of XXXX on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter
Electromyography (EMG) Measures in Women with Stress Urinary Incontinence
(SUI).
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group,
Dose-Ranging Study of XXXX in Postmenopausal Women with Overactive Bladder.
- A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group,
Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of XXXX
(7.5mg o.d. with voluntary up-titration to 15mg o.d.) in Patients Aged >
65 Years with Overactive Bladder.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period
Cross-Over Trial to Validate Patient-Reported Outcome Measures for Use in
Men with Late-Onset Hypogonadism.
- A Multi-Center, Double-Blind, Randomized Study to Compare the Efficacy and
Safety of XXXX, 750mg Once Daily for Five Days Versus XXXX Twice Daily for
Ten Days in the Treatment of Complicated Urinary Tract Infection or Acute
Pyelonephritis.
- A Placebo-Controlled, Randomized, Double-Blind, Fixed-Dose, At-Home Study
to Evaluate the Efficacy and Safety of Intranasally Administered XXXX in Subjects
with Erectile Dysfunction.
- A Placebo-Controlled, Randomized, Double-Blind, Fixed-Dose, At-Home Study
to Evaluate the Efficacy and Safety of Intranasally Administered XXXX in Subjects
with Erectile Dysfunction and Diabetes Mellitus.
- A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to
Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations
of Immediate Release and Modified Release Formulations of XXXX in Adult Male
Subjects with Erectile Dysfunction.
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study
of Men with Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy
of XXXX 8 Hours Post-Dose.
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study
of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy
of Viagra 8 Hours Post-Dose.
- A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of
The Efficacy and Safety of XXXX for the Treatment of Symptomatic Benign Prostatic
Hyperplasia.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Evaluation
of the Efficacy and Safety of XXXX in the Treatment of the Signs and Symptoms
of Benign Prostatic Hyperplasia.
- A Placebo-Controlled Randomized, Double-Blind, Parallel-Group, At-Home Exploratory
Study to Evaluate the Efficacy and Safety of Intranasally Administered XXXX
in Subjects with Female Sexual Arousal Disorder (FSAD).
- A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial of
the Efficacy and Safety of XXXX in Women with Mixed Desire/Interest/Arousal/Orgasm
Disorders.
- A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term
Safety Study of Intramuscular Injections of XXXXmg and XXXXmg XXXX in Hypogonadal
Men.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Evaluating
the Efficacy, Safety, and Duration of Erection of Flexible Dose XXXX Administered
for 12 Weeks Compared to Placebo in Subjects with Erectile Dysfunction and
Dyslipidemia.
- A Randomized Double Blind Phase III Study to Evaluate Adjuvant XXXX Treatment
versus Placebo in Patients with Clear Cell RCC and High Risk of Recurrence.
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study
of XXXX on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory
Prostate Cancer.
- A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy
and Safety of XXXX in Extending the Time to Progression of Low-Risk, Localized
Prostate Cancer in Men Who are Candidates for or Undergoing Expectant Management.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group,
Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of
XXXX Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign
Prostatic Hyperplasia.
- A Multicentre, Placebo Controlled, Randomised, Double-Blind, Dose Ranging
Study of XXXX 0.05 MG, 0.1 MG, 0.2 MG, XXXX 4 MG and Placebo Daily Doses for
4 Weeks in Patients Suffering from Overactive Bladder Syndrome.
- A Four-Arm, Randomized, Double-Blind, Parallel, Placebo-Controlled Exploratory
Study of XXXX 0.15 MG, 0.30 MG, and 0.60 MG in Men with Primary Premature
Ejaculation.
- A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety
and Efficacy Trial of XXXX 50 Milligrams Daily and, with Uptitration, 100
Milligrams Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, and Open-Label
Active-Controlled Study To Evaluate the Safety and Efficacy of XXXX Treatment
in Men With Secondary Hypogonadism.
- A Prospective Multicenter, Double-Blinded, Randomized Study to Evaluate
Bleeding Patterns in Women Using One of Three Different Ascending EE Dose
Extended Cycle (91-Day) Oral Contraceptive Regimens Compared to XXXX Oral
Contraceptive Regimen.
- XXXX 5 mg Once a Day Compared to Placebo in Improving Sexual Quality of
Life.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter
Study to Evaluate the Urodynamics Effects of XXXX Once a Day for 12 Weeks
in Men With Signs and Symptoms of Benign Prostatic Hyperplasia.
- A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled
Flexible-Dose Study to Assess the Efficacy and Safety of XXXX in Men with
Erectile Dysfunction Who Do not Self Identify.
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial
of Single-Dose Intravesical XXXX as a Surgical Adjuvant Instilled in the Early
Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive
Bladder Cancer.
- XXXX intermittent IM dosage regimens in patients with symptomatic BPH: a
1 year placebo-controlled efficacy study and long-term safety assessment.
- A Randomized, double-blind, placebo-controlled trial of the safety and efficacy
of XXXX, in patients with lower urinary tract symptoms due to benign prostatic
hypertrophy.
- A Phase III, Open-Label, Multi-Center, Safety and Efficacy Study of Oakwood
Laboratories XXXX for Injectable Suspension 22.5 mg in Patients with Prostate
Cancer.
- A Randomized Double-Blind Parallel Group Study Comparing XXXX 50mg plus
Placebo to XXXX 50mg plus XXXX 3.5mg Administered for 18 months to Men with
Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed
by Rising PSA) Followed by a Two-Year Extension Phase.
- A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled
Study, with Open-Label Follow on, to Evaluate the Efficacy, Safety and Tolerability
of XXXX in Subjects with Premature Ejaculation.
- A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-Center
Long-Term Study to Assess the Safety and Efficacy of the Beta-3 Agonist XXXX
(50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder -
TAURUS
- A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate
the Efficacy and Safety of Two Doses of XXXX Versus Placebo in Women with
Overactive Bladder
- A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety
and Pharmacokinetics of Two 6-Month XXXX Formulations, in Subjects with Prostatic
Adenocarcinoma
- XXXX in patients with symptomatic BPH: an open-labeled safety and efficacy
assessment study.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter
Trial to Evaluate the Efficacy and Safety of a XXXX Flexible Dose Regimen
in Patients with Symptoms of Overactive Bladder including Nocturnal Urinary
Urgency.
- A Randomized, Placebo-Controlled, Double-Blind, Parallel Design, Phase 3
Study to Assess the Safety and Efficacy of XXXX Tablets in Male Subjects with
Erectile Dysfunction.
- Follow up study for REDUCE study subjects.
- An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety
of XXXX in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation
Therapy for Non-Metastatic Prostate Cancer.
- XXXX 2.5mg and 5mg Once a Day Compared to Placebo in Day of Onset of Efficacy.
- A Phase III Randomized, Double Blind, Placebo Controlled, Multicenter Study
to Investigate the Efficacy and Safety of XXXX Nasal Spray Formulation in
Patients with Nocturia.
- A Phase III Open Label Extension Study to Investigate the Safety of XXXX
Nasal Spray Formulations in Patients with Nocturia Completing Study SPC-SER120-DB1-200901
or Study SPC-SER120-DB2-200902.
- An Open-Label Phase 3 Study to Evaluate the Long-Term Safety and Efficacy
of XXXX Tablets in Male Subjects with Erectile Dysfunction.
- A Phase 2 Clinical Study to Evaluate Daily Oral Doses of XXXX for 24 weeks
in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement
Secondary to Benign Prostatic Hyperplasia (BPH)
- A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency
Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of
Two Oral Doses of XXXX in a Randomized, Double-Blind, Placebo-Controlled,
Parallel Group Study in Men with Premature Ejaculation.
- A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,
Multicenter Study of the Efficacy and Safety of XXXX in Men with Premature
Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodietsterase-5
Inhibitor
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group
Study of the Efficacy and Safety of Intraporostatic Administration of XXXX
to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- XXXX60 mg Efficacy in Female OAB Patients Refractory to Detrol LA 4mg Daily.
A Multi-Center, Double-Blind, Placebo-Controlled Trial of XXXX60 mg Daily
in Female OAB Patients on Multiple Concomitant Medications Refractory to Detrol
LA 4mg Daily
- A Prospective Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,
Multicenter Study of the Efficacy and Safety of XXXX in Men with Premature
Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase-5
Inhibitor
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group
Study of the Efficacy and Safety of Intraprostatic Administration of XXXX
to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- An Adaptive Phase 2B/3, Double-Blind, Randomized, Placebo-Controlled Study
to Establish the Dosage Efficacy, and Safety of XXXX in Treating Lower Urinary
Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment-Naive
Male Subjects
- A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency
Time (IELT), Safety, Tolerbility, Pharmacokinetics and Pharmacodynamics of
Two Oral Doses of XXXX in a Randomized, Double Blind, Placebo-Controlled,
Parallel Group Study in Men with Premature Ejaculation
- An Open-Label, Six-Month Extension of Protocol MCS-2-US-a to Further Evaluate
the Efficacy and Safety of XXXX for the Treatment of Lower Urinary Tract Symptoms
Suggestive of Benign Prostatic Hyperplasia in Treatment-Naive Male Subjects
- A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix with Goserelin
Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Prostate Size
Reduction in Prostate Cancer Patients of Intermediate-To-Hig Risk, Who Require
Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
- A Randomized Controlled, Open Label Trial of Degarelix Intermittent Therapy
vs Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in
Patients with Carcinoma of the Prostate with Biochemical Failure after Localized
Therapy
- A Pilot, Multicenter, Double-Blind, Placebo-Controlled, Dose-Escalation
Study of the Safety and Efficacy of XXXX in Patients with Idiopathic Overactive
Bladder and Urinary Incontinence
- A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of XXXX
vs Bicalutamide in Castrate Men with Metastatic Prostate Cancer.
- Phase II, Open Label, Dose Finding Study of the Effect of XXXX on Total and Free Testosterone Levels in Men with Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of XXXX Nasal Spray Formulations in Patients with Nocturia
|
